Literature DB >> 28845518

Neurodevelopmental disorders in children with neurofibromatosis type 1.

Alecia C Vogel1, David H Gutmann2, Stephanie M Morris2.   

Abstract

Over the past several decades, neurofibromatosis type 1 (NF1) has become increasingly recognized as a neurodevelopmental disorder conferring increased risk for several important neurodevelopmental problems. In this review, we summarize the specific neurodevelopmental problems encountered in the context of NF1. These include impairments in general cognitive function, deficits in specific cognitive domains such as executive function and visuospatial processing and risk for specific learning disorders, impairments in attention and social skills and the overlap with attention-deficit-hyperactivity disorder and autism spectrum disorder, and the risk of developing other psychiatric conditions including anxiety and depression. Early recognition of these developmental impairments is important for the effective treatment of children with NF1, and further characterization is essential to improve our understanding of how mutations in the NF1 gene create the diversity of clinical neuropsychiatric symptomatology observed in this at-risk population.
© 2017 Mac Keith Press.

Entities:  

Mesh:

Year:  2017        PMID: 28845518     DOI: 10.1111/dmcn.13526

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  17 in total

1.  The value of screening tests in children with neurofibromatosis type 1 (NF1).

Authors:  Eloïse Baudou; Yves Chaix
Journal:  Childs Nerv Syst       Date:  2020-06-10       Impact factor: 1.475

2.  Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental Disorders.

Authors:  Jessica A Kaczorowski; Taylor F Smith; Amanda M Shrewsbury; Leah R Thomas; Valerie S Knopik; Maria T Acosta
Journal:  Behav Genet       Date:  2020-02-05       Impact factor: 2.805

3.  Nf1 deletion results in depletion of the Lhx6 transcription factor and a specific loss of parvalbumin+ cortical interneurons.

Authors:  Kartik Angara; Emily Ling-Lin Pai; Stephanie M Bilinovich; April M Stafford; Julie T Nguyen; Katie X Li; Anirban Paul; John L Rubenstein; Daniel Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

Review 4.  An executive functioning perspective in neurofibromatosis type 1: from ADHD and autism spectrum disorder to research domains.

Authors:  Taylor F Smith; Jessica A Kaczorowski; Maria T Acosta
Journal:  Childs Nerv Syst       Date:  2020-07-03       Impact factor: 1.475

5.  Fronto-Parietal and White Matter Haemodynamics Predict Cognitive Outcome in Children with Moyamoya Independent of Stroke.

Authors:  Eun Jung Choi; Robyn Westmacott; Fenella J Kirkham; Amanda Robertson; Prakash Muthusami; Manohar Shroff; Mahendranath Moharir; Tricia Williams; Peter Dirks; Daune MacGregor; Mahmoud Slim; Elizabeth Pulcine; Ishvinder Bhathal; Matsanga Leyila Kaseka; Andrea Kassner; William Logan; Gabrielle deVeber; Nomazulu Dlamini
Journal:  Transl Stroke Res       Date:  2022-03-25       Impact factor: 6.800

6.  Predictors of cognitive development in children with neurofibromatosis type 1 and plexiform neurofibromas.

Authors:  Yang Hou; Taryn Allen; Pamela L Wolters; Mary Anne Toledo-Tamula; Staci Martin; Andrea Baldwin; Stephanie Reda; Andy Gillespie; Anne Goodwin; Brigitte C Widemann
Journal:  Dev Med Child Neurol       Date:  2020-02-12       Impact factor: 4.864

7.  Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1.

Authors:  Elizabeth I Pierpont; Rebekah L Hudock; Allison M Foy; Margaret Semrud-Clikeman; Mary Ella Pierpont; Susan A Berry; Ryan Shanley; Nathan Rubin; Katherine Sommer; Christopher L Moertel
Journal:  J Neurodev Disord       Date:  2018-06-18       Impact factor: 4.025

8.  A rare disease and education: Neurofibromatosis type 1 decreases educational attainment.

Authors:  Edvard Johansson; Roope A Kallionpää; Petri Böckerman; Juha Peltonen; Sirkku Peltonen
Journal:  Clin Genet       Date:  2021-01-12       Impact factor: 4.438

9.  The TAND checklist: a useful screening tool in children with tuberous sclerosis and neurofibromatosis type 1.

Authors:  Francesca Cervi; Veronica Saletti; Katherine Turner; Angela Peron; Sara Bulgheroni; Matilde Taddei; Francesca La Briola; Maria Paola Canevini; Aglaia Vignoli
Journal:  Orphanet J Rare Dis       Date:  2020-09-07       Impact factor: 4.123

10.  Brain Tumors in NF1 Children: Influence on Neurocognitive and Behavioral Outcome.

Authors:  Matilde Taddei; Alessandra Erbetta; Silvia Esposito; Veronica Saletti; Sara Bulgheroni; Daria Riva
Journal:  Cancers (Basel)       Date:  2019-11-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.